Vontobel Holding Ltd. Reduces Stock Holdings in Medpace Holdings, Inc. $MEDP

Vontobel Holding Ltd. cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 57.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 955 shares of the company’s stock after selling 1,267 shares during the quarter. Vontobel Holding Ltd.’s holdings in Medpace were worth $491,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. State of Wyoming grew its position in shares of Medpace by 24.6% in the first quarter. State of Wyoming now owns 365 shares of the company’s stock valued at $111,000 after purchasing an additional 72 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Medpace by 9.0% in the 1st quarter. Canada Pension Plan Investment Board now owns 47,400 shares of the company’s stock valued at $14,442,000 after buying an additional 3,900 shares in the last quarter. Royal Bank of Canada grew its holdings in Medpace by 0.7% during the 1st quarter. Royal Bank of Canada now owns 48,732 shares of the company’s stock valued at $14,849,000 after buying an additional 334 shares during the last quarter. Focus Partners Advisor Solutions LLC increased its position in Medpace by 55.8% during the first quarter. Focus Partners Advisor Solutions LLC now owns 1,097 shares of the company’s stock worth $334,000 after buying an additional 393 shares in the last quarter. Finally, Maverick Capital Ltd. acquired a new position in shares of Medpace in the first quarter worth $3,116,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on MEDP shares. Mizuho increased their price objective on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Robert W. Baird set a $613.00 target price on shares of Medpace in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $490.82.

Medpace Price Performance

NASDAQ MEDP opened at $569.98 on Tuesday. The company has a market cap of $16.06 billion, a P/E ratio of 39.86, a P/E/G ratio of 2.14 and a beta of 1.43. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26. The company has a 50-day moving average of $580.13 and a 200-day moving average of $484.52.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same period in the previous year, the firm earned $3.01 earnings per share. Medpace’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 387,925 shares of company stock worth $233,386,647 in the last quarter. 20.30% of the stock is owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.